Login to Your Account



Novartis, Conatus $700M deal proves once-doubted class is no FXR-upper

By Randy Osborne
Staff Writer

Tuesday, December 20, 2016

Novartis AG's FXR agonists represent "an excellent first opportunity for combination products" in liver disease, Conatus Pharmaceuticals Inc. CEO Steven Mento told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription